by 
Algae’s ability to produce high-quality oils for nutritional and pharmaceutical applications proved to be an advantage for one company last week.
ABO member BioProcess Algae signed an agreement to provide commercial supplies of algae-derived, Omega-3 rich oils to KD-Pharma Bexbach GmbH, part of Bioseutica BV’s Fats & Lipids Division. KD-Pharma will use the feedstock to produce highly-concentrated vegetable sourced EPA oils.
More details about the agreement are in this NutraIngredients-USA article.
BioProcess Algae’s bioreactors grow algae with carbon dioxide that is captured from ethanol plants at their facility in Shanendoah, Iowa. The high-quality product is attractive to companies that require sustainable feedstocks for everything from Bioseutica BV’s applications, to animal feeds, green chemicals and biofuels.
Deals such as this will help the company expand operations and production, and achieve greater efficiencies and more attractive prices.
It is a growth process that other companies in the algae industry are likely to follow. As companies tap into markets that allow them to expand production, they will be able to leverage that greater production in markets that require far greater volumes—such as fuels and some chemical markets.
